Age-related qualitative shift in emotional behaviour: Paradoxical findings after re-exposure of rats in the elevated-plus maze

Behavioural Brain Research

Volumn 162, Issue 1, 2005, Pages 135-142

  Bessa, J M ^a   Oliveira, M ^a   Cerqueira, J J ^a   Almeida, O F X ^b   Sousa, N ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Aging; Anxiety; Elevated plus maze; One trial tolerance; Open arm avoidance; Rat; Risk assessment

Indexed keywords

MIDAZOLAM;

AGING; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CONTROLLED STUDY; DRUG TOLERANCE; EMOTION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; RISK ASSESSMENT; SEDATION; TRANQUILIZING ACTIVITY;

AGING; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DRUG TOLERANCE; EMOTIONS; ESCAPE REACTION; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MIDAZOLAM; RATS; RATS, WISTAR; TIME FACTORS;

EID: 19444366293     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2005.03.005     Document Type: Article

References (44)

1. C. Arevalo, R. de Miguel, and R. Hernandez-Tristan Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 70 2001 123 131
2. L.J. Bertoglio, and A.P. Carobrez Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety Behav Brain Res 108 2000 197 203
3. L.J. Bertoglio, and A.P. Carobrez Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus-maze Pharmacol Biochem Behav 73 2002 963 969
4. L.J. Bertoglio, and A.P. Carobrez Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats Psychopharmacology 170 2003 335 342
5. L.J. Bertoglio, and A.P. Carobrez Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2 Behav Pharmacol 15 2004 45 54
6. P. Boguszewski, and J. Zagrodska Emotional changes related to age in rats - a behavioral analysis Behav Brain Res 133 2002 323 332
7. A. Chakrabarti, J.E. Ekuta, and E.S. Onaivi Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice Brain Res Bull 45 1998 67 74
8. F. Chaperon, and M.H. Thiebot Behavioral effects of cannabinoid agents in animals Crit Rev Neurobiol 13 1999 243 281
9. D. Craig, A.P. Passmore, K.J. Fullerton, T.R. Beringer, D.H. Gilmore, and V.L. Crawford Factors influencing prescription of CNS medications in different elderly populations Pharmacoepidemiol Drug Saf 12 2003 383 387
10. A.P. Cruz, F. Frei, and F.G. Graeff Ethopharmacological analysis of rat behavior on the elevated plus-maze Pharmacol Biochem Behav 49 1994 171 176
11. G.R. Dawson, and M.D. Tricklebank Use of elevated plus-maze in the search for novel anxiolytic agents Trends Pharmacol Sci 16 1995 33 36
12. G.R. Dawson, S.P. Crawford, K.J. Stanhope, S.D. Iversen, and M.D. Tricklebank One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure Psychopharmacology 113 1994 570 572
13. S.N. Davies, R.G. Pertwee, and G. Riedel Functions of cannabinoid receptors in the hippocampus Neuropharmacology 42 2002 993 1007
14. S.E. File, P.S. Mabbut, and P.K. Hitchcott Characterisation of the phenomenon of "one trial tolerance" to the anxiolytic effect of chlordiazepoxide Psychopharmacology 110 1990 98 101
15. S.E. File, H. Zangrossi, M. Viana, and F.G. Graeff Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology 111 1993 491 494
16. C. Fernandes, and S.E. File The influence of open arm ledges and maze experience in the elevated plus-maze Pharmacol Biochem Behav 54 1996 31 40
17. R. Frussa-Filho, and R.deA. Ribeiro One-trial tolerance to the effects of chlordiazepoxide in the elevated plus-maze is not due to the acquisition of a phobic avoidance of open arms during initial exposure Life Sci 71 2002 519 525
18. G. Griebel, R.J. Rodgers, G. Perrault, and D.J. Sanger Risk assessment behavior: evaluation of the utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol Biochem Behav 57 1997 817 827
19. G. Griebel, G.L. Moreau, F. Jenck, J.R. Martin, and R. Misslin Some critical determinants of the behavior of rats in the elevated plus-maze Behav Proc 29 1993 129 138
20. M. Hascoet, M. Bourin, and A. Couetoux du Tertre Influence of prior test experience on mice behavior using the four-plate test Pharmacol Biochem Behav 58 1997 1131 1138
21. S. Hogg A review of the validity and variability of the elevated plus-maze as an animal model of anxiety Pharmacol Biochem Behav 54 1996 21 30
22. A. Holmes, and A.J. Rodjers Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for qualitative shift in emotional state? Pharmacol Biochem Behav 60 1998 473 488
23. A. Holmes, and A.J. Rodjers Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze Neurosci Biobehav Rev 23 1999 971 980
24. A. Holmes, J.P. Iles, S.J. Mayell, and R.J. Rodgers Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test Behav Brain Res 122 2001 159 167
25. J.T. Imhof, Z.M. Coelho, M.L. Schimtt, G.S. Morato, and A.P. Carobrez Influence of gender and age on performance of rats in the elevated plus-maze Behav Brain Res 56 1993 177 180
26. K.S. Labar, C.A. Cook, D.C. Torpey, and K.A. Welsh-Bohmer Impact of healthy aging on awareness and fear conditioning Behav Neurosci 118 2004 905 915
27. R.G. Lister Ethologically based animal models of anxiety disorders Pharmacol Ther 46 1990 321 340
28. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, and M.G. Cascio The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
29. S. Mato, and A. Pazos Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain Neuropharmacology 46 2004 716 726
30. I.S. McGregor, and R.A. Dielenberg Differential anxiolytic efficacy of a benzodiazepine on first versus second exposure to a predatory odor in rats Psychopharmacology 147 1999 174 181
31. E.S. Onaivi, M.R. Green, and B.R. Martin Pharmacological characterization of cannabinoids in the elevated plus maze J Pharmacol Exp Ther 253 1990 1002 1009
32. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 14 1985 149 167
33. R.J. Rodgers, and J.C. Cole The elevated plus-maze: pharmacology, methodology and ethology S.J. Cooper C.A. Hendrie Ethology and Psychopharmacology 1994 Wiley Chichester 9 44
34. R.J. Rodgers, and J.K. Sheperd Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice Psychopharmacology 113 1993 237 242
35. R.J. Rodgers, N.J.T. Johnson, J.C. Cole, C.V. Dewar, G.R. Kidd, and P.H. Kimpson Plus-maze retest profile: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade in mice Pharmacol Biochem Behav 54 1996 41 50
36. R.J. Rodgers, N.J.T. Johnson, J. Carr, and T.P. Hodgson Resistance of experientially induced changes in murine plus-maze behavior to altered retest conditions Behav Brain Res 6 1997 71 77
37. R.J. Rodgers, J. Haller, J. Halasz, and E. Mikics 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze Eur J Neurosci 17 2003 1279 1286
38. F. Rodriguez de Fonseca, M.R. Carrera, M. Navarro, G.F. Koob, and F. Weiss Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal Science 276 1997 2050 2054
39. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 2001 565 572
40. E. Sulcova, R. Mechoulam, and E. Fride Biphasic effects of anandamide Pharmacol Biochem Behav 59 1998 347 352
41. M.H. Tehrani, C.A. Tate, and M.I. al-Dahan Age-related levels of GABA/benzodiazepine binding sites in cerebrum of F-344 rats: effects of exercise Neurobiol Aging 16 1995 199 204
42. D. Treit, J. Menard, and C. Royan Anxiogenic stimuli in the elevated plus-maze Pharmacol Biochem Behav 44 1993 463 469
43. E. Valjent, J.M. Mitchell, M.J. Besson, J. Caboche, and R. Maldonado Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine Br J Pharmacol 135 2002 564 578
44. S.I. Wikinski, G.B. Acosta, M.C. Gravielle, C.D. Bonavita, V. Bisagno, and S. Fiszer de Plazas Diazepam fails to potentiate GABA-induced chloride uptake and to produce anxiolytic-like action in aged rats Pharmacol Biochem Behav 68 2001 721 727